Targeting a specific protein in drug-resistant breast cancer cells
Targeting eIF4A1 in drug-resistant breast cancer stem-like cells
This study is looking at how a specific protein called eIF4A1 affects breast cancer stem cells that don't respond well to treatment, especially in African American patients with triple-negative breast cancer, to find new ways to improve their treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Toledo Health Sci Campus NIH-funded |
| Lab location | 1 site (Toledo, United States) |
| Project ID | NIH-11014025 on NIH RePORTER |
What this research studies
This research investigates the role of the eIF4A1 protein in breast cancer stem-like cells that are resistant to treatment, particularly focusing on African American patients with triple-negative breast cancer (TNBC). The study aims to understand how this protein contributes to cancer stemness and treatment resistance, which is a significant challenge in managing TNBC. By exploring the differences in cancer behavior between African American and European White patients, the research seeks to identify new therapeutic targets that could improve treatment outcomes. The approach includes analyzing the biological mechanisms of cancer stem cells and their response to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American women diagnosed with triple-negative breast cancer who have experienced treatment resistance.
Not a fit: Patients with non-triple-negative breast cancer or those who do not identify as African American may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for drug-resistant breast cancer, particularly for African American women.
How similar studies have performed: Previous research has shown promising results in targeting cancer stem cells, but this specific approach focusing on eIF4A1 in TNBC is relatively novel.
Where this research is happening
Toledo, United States
- University of Toledo Health Sci Campus — Toledo, United States (Active)
Researchers
- Principal investigator: Raman, Dayanidhi — University of Toledo Health Sci Campus
- Study coordinator: Raman, Dayanidhi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.